Sep 22 2021 |
MEI Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference |
PDF |
Sep 3 2021 |
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Sep 2 2021 |
MEI Pharma Reports Fiscal Year 2021 Results and Operational Highlights |
PDF |
Sep 2 2021 |
MEI Pharma to Present at Two Healthcare Conferences |
PDF |
Aug 26 2021 |
MEI Pharma to Release 2021 Fiscal Year End Financial Results and Provide Corporate Update on September 2, 2021 |
PDF |
Aug 17 2021 |
MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma |
PDF |
Aug 5 2021 |
MEI Pharma Announces Planned Chief Financial Officer Transition |
PDF |
Aug 2 2021 |
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
PDF |
Jul 7 2021 |
MEI Pharma Appoints Tina C. Beamon, J.D., as Chief Compliance Officer |
PDF |
Jul 1 2021 |
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
PDF |